8-K: Avadel Receives Higher Bid from Lundbeck

Avadel Pharmaceuticals' board deems an unsolicited $23.00 per share offer from Lundbeck potentially superior to its existing $20.00 per share deal with Alkermes.

Summary

• Avadel Pharmaceuticals plc received an unsolicited acquisition proposal from H. Lundbeck A/S.
• The Lundbeck proposal is for up to $23.00 per ordinary share, consisting of $21.00 cash at closing and a non-transferable contingent value right (CVR) of up to $2.00.
• The CVR from Lundbeck includes $1.00 if LUMRYZ and valiloxybate collectively reach $450 million in U.S. annual net sales by December 31, 2027, and another $1.00 if they reach $700 million by December 31, 2030.
• Avadel previously entered into a definitive transaction agreement with Alkermes plc on October 22, 2025, for up to $20.00 per ordinary share.
• The Alkermes deal consists of $18.50 cash at closing and a CVR of $1.50, contingent upon final FDA approval of LUMRYZ for idiopathic hypersomnia by the end of 2028.
• Avadel's Board of Directors, after consulting advisors, determined the Lundbeck Proposal is reasonably expected to result in a "Company Superior Proposal" as defined in the Alkermes agreement.
• This determination allows Avadel to provide information to and negotiate with Lundbeck, but does not permit termination of the Alkermes agreement or entry into a new agreement with Lundbeck yet.
• The Board has not yet determined that the Lundbeck Proposal is a Company Superior Proposal and has not changed its recommendation for the Alkermes acquisition.
• Lundbeck must announce a firm intention to make an offer or withdraw by 5:00 p.m. (U.S. Eastern Time) on the seventh day prior to the Avadel shareholder meeting for the Alkermes acquisition.

Sentiment

Score: 8

Explanation: The filing indicates a significantly positive development for Avadel shareholders due to a higher unsolicited acquisition proposal from Lundbeck, which the board deems potentially superior. This creates a competitive bidding scenario, likely leading to an increased acquisition price or more favorable terms for Avadel. While there's no guarantee of a definitive deal with Lundbeck, the current situation strongly suggests enhanced shareholder value.

Positives

• Lundbeck's unsolicited proposal offers a higher potential value of up to $23.00 per share compared to Alkermes' up to $20.00 per share.
• The cash component of the Lundbeck offer is higher at $21.00 per share versus Alkermes' $18.50 per share.
• The CVR structure in the Lundbeck proposal is tied to sales milestones of LUMRYZ and valiloxybate, potentially offering more direct upside from product performance.
• The Avadel Board's determination that the Lundbeck proposal is "reasonably expected to result in a Company Superior Proposal" indicates a potential for increased shareholder value.
• The competitive interest from Lundbeck could lead to a higher offer from either party, benefiting Avadel shareholders.

Negatives

• There is no certainty that discussions with Lundbeck will result in a definitive agreement or that Lundbeck will make a firm offer.
• The Avadel Board has not yet changed its recommendation in support of the Alkermes acquisition, indicating the Lundbeck proposal is still under evaluation and not definitive.
• The CVRs in both proposals are contingent and not guaranteed, depending on future events (sales targets for Lundbeck, FDA approval for Alkermes).
• The process introduces uncertainty and potential delays in the acquisition timeline.
• Costs related to the acquisition process, including potential legal and advisory fees, will be incurred.

Risks

• The ability of the parties to consummate the acquisition in a timely manner or at all.
• Satisfaction (or waiver) of conditions to the acquisition, including shareholder and regulatory approvals.
• The potential impact of the unsolicited proposal from Lundbeck or the possibility of more competing offers.
• Potential delays in consummating the acquisition.
• The ability of Avadel to timely and successfully achieve the anticipated benefits of the acquisition.
• The impact of health pandemics on the parties' respective businesses.
• The occurrence of any event, change, or circumstance that could lead to the termination of the transaction agreement with Alkermes.
• The effect of the announcement or pendency of the acquisition on Avadel's business relationships, operating results, and business generally.
• Costs related to the acquisition.
• The outcome of any legal proceedings that may be instituted against the parties or any of their respective directors or officers related to the transaction agreement or the acquisition.
• No certainty that the unsolicited proposal from Lundbeck will result in a definitive agreement for an alternative business combination transaction.

Future Outlook

Avadel's Board of Directors has determined that the unsolicited proposal from Lundbeck is reasonably expected to result in a "Company Superior Proposal" compared to the existing agreement with Alkermes. This opens a path for discussions and negotiations with Lundbeck, potentially leading to a higher acquisition offer for Avadel shareholders. However, there is no assurance that these discussions will result in a definitive agreement or a change in the Board's recommendation for the Alkermes acquisition. The company's expectations and beliefs regarding these matters may not materialize, and actual outcomes could differ materially due to various risks and uncertainties.

Management Comments

• Avadel's Board of Directors has determined in good faith, after consultation with its financial and legal advisors, that the Lundbeck Proposal would reasonably be expected to result in a Company Superior Proposal as defined in Avadel's existing transaction agreement with Alkermes plc.
• Avadel's Board has not determined that the Lundbeck Proposal in fact constitutes a Company Superior Proposal under the existing transaction agreement with Alkermes and has not changed its recommendation in support of the Alkermes acquisition at this time.
• There can be no assurance that the discussions with Lundbeck will result in a determination by Avadel's Board that the Lundbeck Proposal is a Company Superior Proposal.
• Avadel will have no further comment on the Lundbeck Proposal until the Board has completed discussions and/or negotiations with Lundbeck.

Industry Context

This development highlights the competitive landscape within the biopharmaceutical sector, particularly for companies with approved or late-stage assets like Avadel's LUMRYZ for narcolepsy and valiloxybate. The unsolicited bid from Lundbeck, a global pharmaceutical company, suggests strong interest in Avadel's product pipeline and market position, potentially indicating a perceived undervaluation in the initial Alkermes deal or a strategic fit for Lundbeck's portfolio. Such competitive bidding scenarios are common in the M&A space for companies with valuable intellectual property or market access.

Comparison to Industry Standards

• The competitive bidding process, where an unsolicited proposal emerges after an initial definitive agreement, is a standard M&A dynamic in the pharmaceutical industry, often seen when assets are highly sought after.
• The use of Contingent Value Rights (CVRs) is a common mechanism in biopharma acquisitions to bridge valuation gaps and share future upside, particularly for assets with regulatory or commercial milestones. For example, the acquisition of Acceleron Pharma by Merck included a CVR tied to the approval of sotatercept.
• The premium offered by Lundbeck (up to $23.00 vs. $20.00 from Alkermes) represents a significant increase, which is typical in competitive situations where bidders see strategic value.
• The requirement for shareholder and regulatory approvals for such transactions is standard practice across the industry.

Legal Proceedings

• The filing mentions a risk of "the outcome of any legal proceedings that may be instituted against the parties or any of their respective directors or officers related to the transaction agreement or the acquisition." This is a general risk disclosure, not a specific ongoing proceeding.

Stakeholder Impact

• Shareholders: Potential for increased acquisition value due to competitive bidding, leading to a higher return on investment. However, uncertainty regarding the final outcome and potential delays exist.
• Employees: Potential for changes in management, corporate culture, or operational structure depending on which company ultimately acquires Avadel.
• Customers: Potential for changes in product focus, support, or pricing strategies for LUMRYZ and valiloxybate, depending on the acquiring entity's strategic vision.
• Suppliers: Potential for renegotiation of contracts or changes in supply chain relationships post-acquisition.
• Creditors: The acquisition could impact the company's debt structure and credit profile, depending on the financing of the deal.

Next Steps

• Avadel will provide information to and conduct discussions and negotiations with Lundbeck regarding its unsolicited proposal.
• Avadel shareholders will need to read the definitive proxy statement (including the scheme document) and other relevant documents filed with the SEC before making any voting decision on the acquisition.
• Lundbeck must, by no later than 5:00 p.m. (U.S. Eastern Time) on the seventh day prior to the Avadel shareholder meeting for the Alkermes acquisition, either announce a firm intention to make an offer or announce that it does not intend to make such an offer.
• Avadel will file a definitive proxy statement (which will include the scheme document) with the SEC.
• Avadel will establish a record date for voting at shareholder meetings to approve the acquisition.

Key Dates

Recommendation

The unsolicited proposal from Lundbeck, which is significantly higher than the existing Alkermes offer and deemed potentially superior by Avadel's board, creates a strong likelihood of an increased acquisition price for Avadel shares. This competitive bidding scenario typically drives up the value for shareholders. While there's no guarantee of a definitive deal with Lundbeck, the current situation presents a clear arbitrage opportunity or at least a floor for a higher offer, making it a strong buy for investors seeking short-term gains from M&A activity.

Keywords

Avadel Pharmaceuticals, AVDL, Alkermes, ALKS, Lundbeck, acquisition, takeover, merger, unsolicited proposal, contingent value right, CVR, LUMRYZ, valiloxybate, biopharmaceutical, narcolepsy, idiopathic hypersomnia, SEC filing, 8-K